drugset
drugset / Trial / NCT05056519

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

NCT05056519 ↗

Phase 1 Unknown 160 enrolled Changchun BCHT Biotechnology Co. He Bei province Center for Disease control and prevention · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase Ⅰ trail is to evaluate the safety of LAVI(non freeze-dried). The secondary objective is to evaluate the immunogenicity of LAVI(non freeze-dried).

Timeline

Start
2021-09-20
Primary completion
2021-12-30
Completion
2022-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine — —

Indications

No indication recorded.